PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory ...

In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous adverse events, including bullous pemphigoid and lipodystrophy.

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 ...

As a part of the review of the supplemental marketing application ... including those with PD-L1 low expression, PD-L1 high expression, squamous and non-squamous histologies.

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical ...